| Patient | Lili Boulanger |
|---|---|
| Date of birth | 2004-08-21 |
| Identifiers | MRN HR-ET025-SYN; SSN (made up) 000-25-7731 |
| Document date | 2026-04-13 |
| Author | Odile Marchetti-Rowe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Vomiting and watery diarrhea since yesterday. [S]
Ms. Boulanger is a 21-year-old woman with ileocolonic Crohn disease, ten weeks into risankizumab and in clinical remission since the prednisone taper ended three weeks ago. Yesterday evening she developed sudden nausea and vomiting, six times overnight, then watery, non-bloody diarrhea eight times since, with cramping across the whole abdomen, aching, and a temperature of 37.8 °C at home. Two of her fellow musicians in the same rehearsal group were ill with the same symptoms this week. She has had no antibiotics. She is keeping down small sips. She wanted to know whether this was her Crohn disease returning and whether she should delay her next risankizumab dose. [S]
| Element | Detail |
|---|---|
| Onset | Sudden, yesterday evening |
| Location | Whole abdomen, cramping |
| Duration | About 18 hours |
| Character | Vomiting, then watery non-bloody diarrhea |
| Severity | Moderate; mild dehydration |
| Context | Contacts ill with the same symptoms; no antibiotics; on risankizumab |
| Modifying factors | Small sips tolerated since this morning |
| Associated signs and symptoms | Low-grade fever, aching; no blood, no right lower quadrant pain like her Crohn pain |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Low-grade fever and aching |
| Gastrointestinal | Positive | Vomiting and watery diarrhea; no blood; cramps across the whole abdomen |
| Genitourinary | Positive | Passing less urine than usual |
| Cardiovascular | Positive | Light-headed on standing |
| Integumentary | Negative | No rash or yellowing |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs | One or two tablets up to every 6 hours as needed | Oral route | 2025-12-15 | active | S |
| Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect | 40 mg each morning, tapering by 5 mg weekly | Oral route | 2026-01-28 to 2026-03-24 | completed | S |
| Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction) | One infusion every 4 weeks for three doses | Intravenous route | 2026-02-02 to 2026-04-26 | completed | S |
| Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single dose | Single infusion | Intravenous route | 2026-02-02 to 2026-02-02 | completed | S |
| Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-01-28 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone | One tablet daily with food | Oral route | 2026-01-28 to 2026-03-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 160 | cm | S |
| 2026-04-13 | Body weight | 46.9 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 18.3 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 98 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 98 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 37.7 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | Leukocytes [#/volume] in Blood by Automated count | 9.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-13 | C reactive protein [Mass/volume] in Serum or Plasma | 11 | mg/L | <=5 mg/L | High | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 3.4 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | <=33 U/L | Normal | S |
Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired, mildly dehydrated; temperature 37.7 °C; heart rate 98 |
| Mouth | Dry mucous membranes; no ulcers |
| Abdomen | Soft, mildly tender everywhere without guarding; active bowel sounds; no right lower quadrant mass |
| Perianal | Normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled | active | confirmed | K50.80 | S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed. |
| Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked | resolved | confirmed | R19.7 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D). |
| Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) | active | confirmed | D50.0 | S — Synthetic finding at presentation; corrected by intravenous iron. |
| Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support. |
| Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at presentation. |
| Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease | active | confirmed | Z79.620 | S — Synthetic treatment status. |
| Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three days | resolved | confirmed | A08.11 | S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness. |
Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2026 (2026); 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis 2017;65(12):e45-e80 (2017)
Follow-up: Telephone check in two days. IBD review as planned at the first maintenance dose. Next scheduled visit 2026-04-27: review at week 12, the first maintenance dose of risankizumab. [S]